Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01137968 · ClinicalTrials.gov registry record · Phase 2
Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC)
A Phase 2 study, sponsored by Geron Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 116
- Enrollment target
NCT01137968 is a Phase 2 study that has completed, run by Geron Corporation. The registered enrollment target is 116 participants.
The verdict
NCT01137968, a Phase 2 study, has completed, sponsored by Geron Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 116 participants
- Enrollment target
Study Summary
The purpose of this is to evaluate the efficacy and safety of imetelstat (GRN163L) as maintenance therapy for patients with advanced stage NSCLC who have not progressed after 4 cycles of platinum based therapy. Participants will be randomized in a 2:1 ratio to imetelstat + standard of care versus standard of care alone. Participants who received bevacizumab with their induction chemotherapy will continue to receive bevacizumab on this study.
Interventions
- DRUG Bevacizumab
- DRUG imetelstat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2010-05 |
| Est. Completion | 2013-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01137968
The ClinicalTrials.gov registry entry for NCT01137968 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 116 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Geron Corporation, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bevacizumab is the first listed.
NCT01137968 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01137968 about?
NCT01137968 is a clinical study titled "Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC)". The purpose of this is to evaluate the efficacy and safety of imetelstat (GRN163L) as maintenance therapy for patients with advanced stage NSCLC who have not progressed after 4 cycles of platinum based therapy. Participants will be randomized in a 2:1 ratio to imetelstat + standard of care versus s...
What is the current status of trial NCT01137968?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 116 participants. The study started on 2010-05. Estimated completion is 2013-09.
What interventions are being tested in trial NCT01137968?
The interventions under investigation include: Bevacizumab (DRUG), imetelstat (DRUG).
Who is sponsoring clinical trial NCT01137968?
This trial is sponsored by Geron Corporation, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.